Levosimendan Increases Survival in a D-Galactosamine and Lipopolysaccharide Rat Model

Levosimendan, a calcium sensitizer, has an organ protective profile through the inhibition of inflammatory mediators and cytokines in critical conditions, such as heart failure, ischemia-reperfusion injury, and sepsis. The survival effect of levosimendan for acute liver failure has not been examined yet. Male Sprague-Dawley rats were examined in the D-galactosamine hydrochloride and lipopolysaccharide (GalN/LPS) model. Levosimendan was injected intraperitoneally before GalN/LPS treatment. Survival was monitored for 7 days. For biochemical analyses, liver and blood samples were collected from the rats at 1 and 8 h after GaIN/LPS treatment. The pretreatment of levosimendan at 4 mg/kg significantly increased survival in GalN/LPS rats. In the liver specimen, levosimendan significantly inhibited the activation of nuclear factor-κB (NF-κB) at 1 h, and significantly decreased the mRNA expression of inflammatory mediators, including inducible nitric oxide synthase and tumor necrosis factor-α (TNF-α), at 8 h. In serum, levosimendan decreased the levels of nitrite, a metabolite of nitric oxide, and TNF-α protein, as well as aspartate aminotransferase and alanine aminotransferase. These results indicated that Levosimendan ameliorated liver dysfunction and survival in acute liver failure model rats through the suppression of NF-κB activation

Two cases of 18F‐FDG‐PET/CT positive Schloffer tumor following curative surgery of colon cancer

Abstract We report two cases of Schloffer tumor that required resection after radical colon cancer surgery because of suspected lymph node recurrence on contrast‐enhanced (CE) CT and 18F‐FDG‐PET/CT. Case1 is a 69‐year‐old man with sigmoid colon cancer pStage IIA, and case2 is a 61‐year‐old man with descending colon cancer pStage IIIB

Evaluating the Relationships between the Postural Adaptation of Patients with Profound Cerebral Palsy and the Configuration of the Seating Buggy's Seating Support Surface

We are currently investigating the physiological polymorphism of wheelchair users with profound cerebral palsy and the properties of the Seating Buggy (developed by S. Nishimura, 1998) to clarify important and general elements of wheelchairs for widespread use. Cerebral palsy is a diagnostic term used to describe a group of motor syndromes resulting from disorders in early brain development. Recently, it has been shown that the Seating Buggy produces functional head-neck alignments and active control of sitting balance for people with profound cerebral palsy. The Seating Buggy is a wheelchair for the profoundly disabled and features a wide adjustment range from heights of 120 cm to 175 cm. Its seating support surface is comprised of a sling-seat. To examine the relationships between the postural adaptation of patients with profound cerebral palsy and the configuration of the Seating Buggy's seating, we assessed the postural alignment of the Seating Buggy's user and then measured the configuration of its resulting seating support surface with a three dimensional scanning system. Twenty-one subjects were used for the purposes of this investigation in their everyday environment. Postural adaptation and wheelchair fitting in the Seating Buggy were assessed from the viewpoint of the Active Balanced Seating by a seating expert. The subjects fell into two categories, as follows: 11 for appropriate or nearly appropriate fitting, and 10 for ill-fitting. The depth of thoracic support and the forward distance of lumbar support for those who claimed that it was ill-fitting were significantly reduced compared with that of those who claimed that the Seating Buggy offered an appropriate or nearly appropriate fitting. It was suggested that the properly adjusted depth of thoracic support and distance of the lumbar support were related to the resulting satisfactory head-neck alignment and sitting balance of the patients with profound cerebral palsy

Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models

令和4年

Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models

令和4年

Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model

Lenvatinib has a high response rate in unresectable advanced hepatocellular carcinoma (HCC). In this study, we investigated whether lenvatinib-incorporating poly(ε-caprolactone) sheets (lenvatinib sheets) as a drug delivery system (DDS) exerted antitumor effects in a murine HCC model. The lenvatinib sheets were designed for sustained release of approximately 1 mg lenvatinib for 14 days. For 14 days, 1 mg lenvatinib was orally administered to mice. Then, we compared the antitumor effects of lenvatinib sheets with those of oral lenvatinib. The tumor volume, body weight, and serum lenvatinib level were measured for 14 days. A peritoneal dissemination model was established to examine the survival prolongation effect of the lenvatinib sheets. Tumor growth was significantly inhibited in the lenvatinib sheet group compared with that in the no treatment and oral groups. The antitumor effect was significantly higher in the lenvatinib sheet group. Regardless of the insertion site, the serum lenvatinib levels were maintained and showed similar antitumor effects. The mitotic index was significantly inhibited in the lenvatinib sheet group compared with that in the control group. Furthermore, lenvatinib sheets improved the 30-day survival. Lenvatinib sheets showed sufficient antitumor effects and may serve as an effective novel DDS for advanced HCC

Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model

令和4年